GeneHealth - Your precision medicine

Bartter Disease Type 1

Disease Details

Family Health Simplified

Buy Membership

Description: Bartter disease type 1 is a rare inherited disorder characterized by impaired salt reabsorption in the kidneys, leading to dehydration, low blood potassium levels, and metabolic alkalosis.

One-sentence description: Bartter disease type 1 is a genetic disorder that affects kidney function, causing electrolyte imbalances and associated symptoms.
Type: Bartter syndrome type 1 is a genetic disorder characterized by defective function of the kidney's ion transport mechanisms. It is inherited in an autosomal recessive manner, meaning that an individual needs to inherit two copies of the defective gene, one from each parent, to develop the condition.
Signs And Symptoms: Bartter syndrome type 1 is characterized by a range of signs and symptoms, including:

- Hypokalemia (low potassium levels)
- Metabolic alkalosis (high blood pH)
- Hypercalciuria (excessive calcium in urine)
- Polyuria (frequent urination)
- Polydipsia (excessive thirst)
- Failure to thrive in infants
- Muscle weakness and spasms
- Growth retardation in children

These symptoms are due to a mutation in the SLC12A1 gene, which affects kidney function. There is no information relevant to "nan" in the context of this disease.
Prognosis: Bartter syndrome type 1 is a rare inherited disorder affecting the kidneys' ability to reabsorb sodium. The prognosis can vary based on the severity of the condition and the effectiveness of treatment. With proper management, including electrolyte supplements and medications to balance potassium levels, many individuals can lead relatively normal lives. However, complications such as growth retardation and developmental delays may occur. Regular monitoring and early intervention are crucial in improving long-term outcomes.
Onset: Bartter disease type 1 typically presents in the prenatal period or early infancy. Symptoms can include polyhydramnios (excess amniotic fluid) during pregnancy, failure to thrive, dehydration, and electrolyte imbalances such as hypokalemia (low potassium levels), hypochloremia (low chloride levels), and metabolic alkalosis.
Prevalence: The exact prevalence of Bartter syndrome type 1 is not well-defined, but it is considered a rare disorder. It is estimated to occur in approximately 1 in 1,000,000 individuals.
Epidemiology: Bartter disease type 1, also known as neonatal Bartter syndrome, is a rare inherited disorder that affects kidney function. Due to its rarity, precise epidemiological data is limited, and the incidence is not well-defined. It has been reported globally, with cases identified in various populations. The condition is typically diagnosed in infancy or early childhood.
Intractability: Bartter syndrome type 1 is considered to be intractable, meaning it is a chronic condition without a cure. Management typically focuses on symptom relief and preventing complications through electrolyte supplementation and medications. Regular monitoring and long-term care are essential.
Disease Severity: Bartter syndrome type 1 is a rare, autosomal recessive disorder affecting the kidneys' ability to reabsorb sodium. Severity can vary, but it is typically a serious condition that presents with symptoms in infancy, including growth retardation, dehydration, muscle weakness, and metabolic alkalosis. If untreated, complications can be severe. Prompt diagnosis and management can improve outcomes.
Healthcare Professionals: Disease Ontology ID - DOID:0110142
Pathophysiology: Bartter disease type 1 is a rare inherited disorder affecting the kidneys. It is caused by mutations in the SLC12A1 gene, which encodes the sodium-potassium-chloride co-transporter (NKCC2) used in the thick ascending limb of the loop of Henle. This results in defective reabsorption of sodium, potassium, and chloride, leading to an imbalance of electrolytes and a range of symptoms including hypokalemia, metabolic alkalosis, hypercalciuria, and elevated renin and aldosterone levels. These electrolyte imbalances can cause muscle weakness, growth retardation, and increased urine production.
Carrier Status: Bartter syndrome type 1 is an autosomal recessive disorder. Carrier status refers to an individual who has one normal allele and one mutated allele of the gene involved, typically the SLC12A1 gene. Carriers usually do not show symptoms of the disease but can pass the mutated gene to their offspring.
Mechanism: Bartter syndrome type 1 is characterized by mutations in the SLC12A1 gene, which encodes the Na-K-2Cl co-transporter (NKCC2) located in the thick ascending limb of the loop of Henle in the kidneys. The molecular mechanism involves a defect in this transporter, leading to impaired reabsorption of sodium, potassium, and chloride ions. This defect results in hypokalemia, metabolic alkalosis, hypercalciuria, and secondary hyperaldosteronism due to the increased distal delivery of sodium and chloride, stimulating increased renal potassium excretion and volume depletion.
Treatment: Bartter Syndrome Type 1 is a rare inherited disorder affecting the kidneys' ability to reabsorb sodium. Treatment typically includes:

1. **Electrolyte Replenishment**: Potassium and magnesium supplements to correct imbalances.
2. **Nonsteroidal Anti-inflammatory Drugs (NSAIDs)**: Indomethacin can reduce prostaglandin levels, thereby decreasing renal sodium loss.
3. **Potassium-Sparing Diuretics**: Such as spironolactone or amiloride to prevent potassium loss.
4. **Angiotensin-Converting Enzyme (ACE) Inhibitors or Angiotensin II Receptor Blockers (ARBs)**: To help manage blood pressure and reduce the effects of aldosterone.

Regular monitoring by a healthcare provider is essential to manage electrolyte levels and prevent complications.
Compassionate Use Treatment: Bartter syndrome type 1 is a rare inherited disorder affecting the kidneys' ability to reabsorb sodium. In terms of compassionate use, off-label, or experimental treatments, some potential options include:

1. **Indomethacin**: An NSAID used off-label to reduce prostaglandin levels, helping to manage electrolyte imbalance and minimize renal potassium loss.

2. **Spironolactone**: A potassium-sparing diuretic used off-label to manage hypokalemia and hyperaldosteronism.

3. **Amiloride**: Another potassium-sparing diuretic, sometimes used off-label for managing hypokalemia.

4. **ACE Inhibitors or ARBs**: Occasionally used off-label to manage hyperreninemia and related complications.

5. **Experimental Treatments**: Ongoing research may explore gene therapy or other novel approaches, but these are typically limited to clinical trials.

Continuous monitoring by healthcare professionals is crucial to tailor the treatment to the patient's specific needs.
Lifestyle Recommendations: #### Bartter Syndrome Type 1: Lifestyle Recommendations

1. **Hydration**:
- Ensure adequate fluid intake to prevent dehydration. Patients with Bartter syndrome may lose significant amounts of electrolytes and fluids through urine.

2. **Diet**:
- Aim for a diet rich in potassium (bananas, oranges, tomatoes) to counteract hypokalemia.
- Include magnesium-rich foods (nuts, seeds, green leafy vegetables) to manage hypomagnesemia.
- Sodium intake might need to be monitored and adjusted based on individual electrolyte levels and guidance from a healthcare provider.

3. **Supplements**:
- Potassium and magnesium supplements are often essential.
- Consider calcium and vitamin D supplementation to support bone health.

4. **Avoidance of NSAIDs**:
- Non-steroidal anti-inflammatory drugs (NSAIDs) should generally be avoided unless specifically advised by a healthcare provider, as they can affect kidney function.

5. **Regular Monitoring and Healthcare Visits**:
- Frequent monitoring of blood and urine electrolytes is crucial to adjust medications and dietary intake.
- Regular visits to a nephrologist or endocrinologist for specialized care.

6. **Activity Level**:
- Engage in moderate physical activities but avoid extreme exertion to prevent excessive loss of fluids and electrolytes.
- Maintain a balanced lifestyle with ample rest and stress management.

7. **Education and Awareness**:
- Educate yourself and family members about the symptoms and management of electrolyte imbalances.
- Be prepared to recognize and respond to signs of dehydration, hypokalemia, or other complications.

8. **Medication Adherence**:
- Strict adherence to prescribed medications, including potassium-sparing diuretics and other treatments aimed at managing electrolyte imbalances.

Always consult with healthcare professionals for a personalized plan tailored to the individual’s specific needs and medical condition.
Medication: For Bartter syndrome type 1, common medications used for management include potassium supplements, magnesium supplements, nonsteroidal anti-inflammatory drugs (like indomethacin), and potassium-sparing diuretics (like spironolactone). These medications help manage electrolyte imbalances and other symptoms associated with the disorder. Always consult with a healthcare provider for the most appropriate treatment plan.
Repurposable Drugs: Bartter syndrome type 1 is a rare inherited disorder affecting kidney function. For potential repurposable drugs, existing treatments for this condition include:

1. **Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)**: Indomethacin is commonly used to reduce prostaglandin production, as excessive prostaglandins contribute to the electrolyte imbalance observed in Bartter syndrome.

2. **Potassium-Sparing Diuretics**: Spironolactone or amiloride may be used to help maintain potassium levels.

3. **Magnesium Supplements**: As individuals with Bartter syndrome often have low magnesium levels, supplements may be required.

4. **Angiotensin-Converting Enzyme (ACE) Inhibitors or Angiotensin II Receptor Blockers (ARBs)**: These can help manage blood pressure and reduce potassium loss.

Any off-label use of medications should be done under medical supervision.
Metabolites: Bartter disease type 1 is a rare inherited disorder affecting the kidneys' ability to reabsorb sodium. Elevated levels of certain metabolites can be found in patients. These include:

- **Prostaglandin E2**: Elevated due to increased renal production.
- **Renin**: Elevated due to the body's response to renal salt wasting.
- **Aldosterone**: Elevated as a compensatory mechanism for sodium loss.
- **Chloride**: Lower in the blood, leading to hypochloremia.
- **Potassium**: Lower in the blood, leading to hypokalemia.

Note: "nan" might refer to "not a number" which is a computational term and unrelated to Bartter disease type 1. If this was intended differently, please provide additional context.
Nutraceuticals: For Bartter disease type 1, there is no specific nutraceutical treatment that has been conclusively proven to be effective. Management typically focuses on conventional medical therapies, such as potassium and magnesium supplements, nonsteroidal anti-inflammatory drugs (NSAIDs), and ACE inhibitors. Always consult with a healthcare provider for appropriate treatment plans.
Peptides: Bartter disease Type 1 is a rare inherited disorder affecting potassium, sodium, and chloride reabsorption in the kidneys. It results from mutations in the SLC12A1 gene coding for the Na-K-2Cl cotransporter (NKCC2). Peptides are not typically associated with the standard treatment or diagnosis. However, the focus is on electrolyte balance, often managed with supplements and medications like potassium-sparing diuretics. "nan" is not applicable in this context regarding peptides and the disease.